Sign inJoin waitlistJoin the waitlist

Saima Waqar

Director of Education-Oncology · Washington University/B-JH/SLCH Consortium

Credentials: · · · · · ·

History

Washington University/B-JH/SLCH Consortium
Present
Education-Oncology · Washington University/B-JH/SLCH Consortium
Present
Washington University/B-JH/SLCH Consortium
Present

Hematology and Medical Oncology
Washington University/B-JH/SLCH Consortium
2004–2007
Internal Medicine
Barnes-Jewish Hospital
2001–2004
Aga Khan University Medical College Pakistan
1997–2001

Research

Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2021 · 442 citations
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
The Lancet Oncology · 2020 · 407 citations
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
Journal of Clinical Oncology · 2018 · 348 citations

DM
Daniel Morgensztern
49 papers
Ramaswamy Govindan
44 papers
Siddhartha Devarakonda
18 papers · 3 as a fellow
Clifford Robinson
17 papers
MB
Maria Baggstrom
11 papers
Pamela Samson
11 papers · 5 as a resident
Varun Puri
11 papers
Jeff Bradley
10 papers
JW
Jeffrey Ward
9 papers
KK
Karen Kelly
9 papers
RH
Roy Herbst
8 papers
Alexander Patterson
7 papers

Clinical trials

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Principal investigator · Recruiting · Phase 2, Phase 3
SWOG Cancer Research Network
2025–2028
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
Principal investigator · Recruiting · Phase 2
Advenchen Pharmaceuticals, LLC.
2022–2028
Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC)
Principal investigator · Withdrawn · Phase 2
Washington University School of Medicine
2016–2020
Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors
Principal investigator · Withdrawn · Phase 1
Washington University School of Medicine
2015–2018